Avandia Continues To Take Its Toll; GSK Restructuring Will Cut $1.5 Bil., Jobs

Due in part to plummeting Avandia sales, GlaxoSmithKline will cut $1.5 billion in costs through a restructuring program targeting sales and manufacturing, the firm announced in a third quarter sales and earnings call Oct. 24